Gynaecology

Women’s health in Calgary gets multi-year boost thanks to $10M investment through Calgary Health Foundation

Retrieved on: 
Friday, May 3, 2024
Education, Management, University, AHS, Investment, Medicine, Woman, Policy, Research, Obstetrics, Gynaecology, Obstetrics and gynaecology, Attention, Osteoporosis, Disease, Mental health, AWHF, Urogynecology, Diagnosis, Breast cancer, Government

Calgary, Alberta, Canada, May 03, 2024 (GLOBE NEWSWIRE) -- Calgary Health Foundation announces a $10M investment over two years from the Government of Alberta in support of women’s health initiatives.

Key Points: 
  • Calgary, Alberta, Canada, May 03, 2024 (GLOBE NEWSWIRE) -- Calgary Health Foundation announces a $10M investment over two years from the Government of Alberta in support of women’s health initiatives.
  • Calgary Health Foundation is committed to further funding female-related clinical care, research, and education.
  • Reproductive health, pelvic floor health, mental health, autoimmune disorders, chronic conditions, and diseases like cardiovascular disease and osteoporosis disproportionally impact women.
  • The $10M investment to Calgary Health Foundation, combined with donor support, will launch women’s health outcomes in a positive direction.

KARL STORZ and Well Lead Medical Announce Exclusive Agreement for Distribution of ClearPetra Stone-Removal System in the U.S.

Retrieved on: 
Thursday, May 2, 2024
Health Technology, Health, Medical Devices, Well, MIT Tech Talk, Urology, Kidney, American Urological Association, Marketing, Cleveland Clinic, MD, PCNL, Gynaecology, FRCSC, Stone, Booth, Master of Science, AUA, KARL, Research institute, Pharmaceutical industry

KARL STORZ United States announces an exclusive agreement with Well Lead Medical to offer the ClearPetra suction-evacuation ureteral access sheath in conjunction with KARL STORZ endoscopic visualization devices for comprehensive urinary stone management.

Key Points: 
  • KARL STORZ United States announces an exclusive agreement with Well Lead Medical to offer the ClearPetra suction-evacuation ureteral access sheath in conjunction with KARL STORZ endoscopic visualization devices for comprehensive urinary stone management.
  • “Our strategic collaboration with Well Lead Medical on ClearPetra represents a major step forward in stone management.
  • “The collaboration between Well Lead Medical and KARL STORZ represents a significant milestone in our commitment to advancing endourology.
  • During the show, KARL STORZ will be sponsoring a Tech Talk on May 4, 10:00–10:25 a.m., at Booth #1733.

Butterfly Medical Welcomes Experienced Urology Executive to its Helm

Retrieved on: 
Saturday, May 4, 2024
BPH, Gastroenterology, Retention rate, Elective surgery, Malignancy, Urology, Gynaecology, Novartis, Patient, MacCarthy Mor dynasty, Butterfly, CE marking, Pharmaceutical industry

With over 20 years of global healthcare leadership experience, Mr. MacCarthy has led teams to successfully commercialize multiple medical devices in fields including gastroenterology, pulmonology, thoracic surgery, gynecology and urology.

Key Points: 
  • With over 20 years of global healthcare leadership experience, Mr. MacCarthy has led teams to successfully commercialize multiple medical devices in fields including gastroenterology, pulmonology, thoracic surgery, gynecology and urology.
  • Mr. MacCarthy was most recently head of the Urology and Gynecology business unit for Olympus America, Inc.
    "We are thrilled to welcome Pat as our new CEO for Butterfly Medical", said Greg Parekh, Chairman of the Board for Butterfly Medical, Managing Partner of New Rhein Healthcare Investors and former Head of M&A at Novartis.
  • "With deep cross-functional expertise in large and start-up healthcare companies, Pat is well positioned to lead Butterfly Medical to clinical and commercial success.
  • "I chose Butterfly Medical because I saw significant value in its unique technology and because of the strength of the management team, clinicians, partners and investors.

Chang Gung Memorial Hospital, Linkou, Garners Two Prestigious International Awards for Its Outstanding Achievements

Retrieved on: 
Tuesday, April 30, 2024
Investment, International Medical Center, Hospital, AI, Proton therapy, Bed, Internal medicine, Pediatrics, Lymphedema, EMRAM, Research, Organ transplantation, Patient safety, Gynaecology, Accreditation, HIMSS, Patient, JCI, Health, Multimedia, Patient satisfaction, Medicine, Nursing

TAOYUAN, April 29, 2024 /PRNewswire/ -- The Healthcare Asia Awards, a prestigious international recognition program, honors exceptional healthcare institutions across Asia for their pioneering achievements in healthcare innovation and patient care. On March 26th, at the 2024 Awards Ceremony held in Singapore, Chang Gung Memorial Hospital, Linkou, Taiwan, emerged victorious, capturing the coveted titles of Hospital of the Year - Taiwan and Smart Hospital Initiative of the Year - Taiwan.

Key Points: 
  • With over 30 departments, Chang Gung Memorial Hospital offers a broad spectrum of services, including internal medicine, surgery, gynecology, and pediatrics.
  • Chang Gung Memorial Hospital not only excels in medical technology and services but also prioritizes patient safety and compassionate care.
  • This year, the Healthcare Asia Awards acknowledged Chang Gung Memorial Hospital in Linkou for its exceptional leadership in medical services, research, and smart healthcare innovations.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/chang-gung-memorial-hospital-li...
    SOURCE Chang Gung Memorial Hospital, Linkou

Boston IVF Welcomes Dr. Josette Dawkins to its Springfield Fertility Center, Further Enhancing Access to Expert Reproductive Care in Western Massachusetts

Retrieved on: 
Monday, April 29, 2024
University, Hysterosalpingography, PCOS, Suite, REI, MD, Fertility, Rochester Regional Health, Baystate, HSG, Obstetrics, IVF, Gynaecology, University of Massachusetts, Family, Medicine, Assistant, IUI, Medical director, Semen analysis, Nursing

SPRINGFIELD, Mass., April 29, 2024 /PRNewswire-PRWeb/ -- Boston IVF, one of the world's most experienced fertility treatment providers, which has assisted in over 150,000 babies born since 1986, is pleased to announce the addition of reproductive endocrinologist, Dr. Josette Dawkins, MD to its Springfield, MA fertility center and team.

Key Points: 
  • The addition of Dr. Josette Dawkins to Boston IVF and its fertility clinic in Springfield enriches the accessibility of timely reproductive care for individuals seeking to start a family.
  • She joins Boston IVF from Baystate Reproductive Medicine in Springfield, MA – where she served as its Medical Director.
  • "We are thrilled to extend a warm welcome to Dr. Josette Dawkins as she joins our esteemed Boston IVF team in Springfield, Massachusetts," expressed David Stern, CEO of Boston IVF.
  • "I am honored to become part of the respected team at Boston IVF," said Dr. Josette Dawkins.

Kirkman(R) Launches Certified Prenatal Supplement

Retrieved on: 
Wednesday, April 24, 2024
Aureus, Thallium, Lead, Heavy metals, Safety, Pregnancy, Health, Prenatal vitamins, Infant, Titanium, OBGYN, Gynaecology, Allergen, Salmonella, Pseudomonas aeruginosa, FIGO, Escherichia coli, P2i, Child, Metal, Toxicity, Aluminium, Staphylococcus aureus, Nickel, Dietary supplement

Portland, Oregon--(Newsfile Corp. - April 24, 2024) - Kirkman®, a premier global leader in the dietary supplement industry, has introduced the first certified prenatal supplement that follows FIGO's (International Federation of Gynecology and Obstetrics) position and recommendation after their October 2023 FIGO Statement.

Key Points: 
  • Portland, Oregon--(Newsfile Corp. - April 24, 2024) - Kirkman®, a premier global leader in the dietary supplement industry, has introduced the first certified prenatal supplement that follows FIGO's (International Federation of Gynecology and Obstetrics) position and recommendation after their October 2023 FIGO Statement.
  • In addition to being recognized as the Top Supplement Manufacturing Company in 2023 by the Food Business Review, Kirkman has developed the P2i by Kirkman prenatal supplement with the support and guidance of OBGYN's, becoming the only Purity-Certified prenatal product in the market.
  • "We are very excited about launching this prenatal supplement to benefit the human development journey.
  • To learn more about P2i by Kirkman and their certified prenatal supplement, visit their website: https://www.kirkmangroup.com/p2i-prenatal.html

SS Innovations International Announces Q1 2024 Company Updates

Retrieved on: 
Monday, April 22, 2024
Hospital, Neck, OTC, Surgeon, Mantra, Urology, Head, Gynaecology, Dentistry

FORT LAUDERDALE, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world class robotic surgery affordable and accessible to a global population, today announced its Q1 2024 Company updates.

Key Points: 
  • FORT LAUDERDALE, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world class robotic surgery affordable and accessible to a global population, today announced its Q1 2024 Company updates.
  • As of March 31, 2024, SS Innovations has completed a total of 32 successful installations of the SSi Mantra Surgical Robotic System in medical facilities across India.
  • For the quarter ended March 31, 2024, SS Innovations sold 8 SSi Mantra Surgical Robotic Systems and expects to report revenues of approximately US $7 million, which exceeds revenues reported for the entire year ended December 31, 2023.
  • In addition, SS Innovations also installed a robotic system at the World Laparoscopy Hospital, which is a prominent Minimal Access Surgery Training Institute in India.

Compass Diversified-Backed The Honey Pot Co. Strengthens Its Board With The Appointment of Three New Directors

Retrieved on: 
Thursday, April 18, 2024
Honey, Astral, Woman, PepsiCo, Jue, Health, Marketing, Johnson & Johnson, Cargill, Growth, Female, Obstetrics, Gynaecology, Knowledge, Entrepreneurship, Carrier oil, Human, Medical device, Booz Allen Hamilton, Honeypot, Beauty, Medical director, Kraft Foods, TED, Management

Prior to Johnson & Johnson, Ms. Smith-Gomez held general management and marketing roles at Mars, Kraft Foods, and PepsiCo.

Key Points: 
  • Prior to Johnson & Johnson, Ms. Smith-Gomez held general management and marketing roles at Mars, Kraft Foods, and PepsiCo.
  • She currently sits on the boards of The New York Academy of Medicine, Envoy Medical Corporation, and Black Public Media.
  • Ms. Wong currently sits on the board of FireFly Automatix and on the advisory board of Versicolor Technologies.
  • “Welcoming Janis, Maria, and JuE to our board is a testament to our commitment to empowering humans and promoting holistic wellness.

GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year

Retrieved on: 
Tuesday, April 16, 2024
Education, Breast cancer, Patient, Cancer, GTG, Global Reach, Comfort, Mammography, Risk, Woman, Breast MRI, Health, ASX, Research, Genetic testing, Growth, Disease, General practice, Gynaecology, Pharmaceutical industry

The geneType team has achieved clinical proof of concept in key markets including general practice, oncology, and gynecology with repeat sales in each of these markets.

Key Points: 
  • The geneType team has achieved clinical proof of concept in key markets including general practice, oncology, and gynecology with repeat sales in each of these markets.
  • Clinicians embracing and offering geneType to patients have tended to be:
    Focussed on offering patients the best available care; and
    Comfortable with explaining results to patients.
  • Clinical adoption of geneType is now in more than 12 US States, Canada and nationally in Australia.
  • “Our success in expanding clinician adoption and growth in sales reflects the growing recognition of the transformative potential of personalized medicine,” remarked Simon Morriss, CEO of GENE.

Novocure Reports First Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 2, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, METIS, Congress, Cancer, Paclitaxel, EDT, Investment, Temozolomide, Food, Survival, Gynaecology, Immunotherapy, Lung cancer, Partnership, GBM, Webcast, Glioblastoma, Disclosure, IND, Prescription, ASCO, Regulation Fair Disclosure, Patient, Brain, Society, Loss, Regulation, PLD, Marketing, Clinical trial, NSCLC, PMA, Investigational New Drug, Pharmaceutical industry

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024.

Key Points: 
  • Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024.
  • Research, development, and clinical studies expenses for the quarter were $51.6 million, a decrease of 14% from the same period in 2023.
  • Sales and marketing expenses for the quarter were $55.2 million, an increase of 8% compared to the same period in 2023.
  • Novocure will host a conference call and webcast to discuss first quarter 2024 financial results at 8:00 a.m. EDT today, Thursday, May 2, 2024.